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Abstract 
Background: Bronchoprovocation challenges use direct or indirect acting stimuli to induce airflow obstruction. Indi-
rect stimuli either non-allergic/non-IgE mediated (e.g. exercise, mannitol) or allergic/IgE mediated (i.e. allergen) trigger 
mast cells to release bronchoconstricting mediators (e.g. cysteinyl leukotrienes, histamine). Performing repeat chal-
lenges within a short timeframe (e.g. 3 h) with non-allergic indirect stimuli results in a diminished, refractory response 
to the second challenge that is inhibited by non-steroidal anti-inflammatory medications. Cross refractoriness occurs 
between indirect stimuli. It follows that repeat bronchoprovocation with allergen might exhibit refractoriness that 
might be altered by ibuprofen. We assessed the response to a second allergen challenge performed 24 h after an 
initial allergen challenge to determine if the response is refractory. If refractoriness developed, the study aimed to 
determine whether a single dose of ibuprofen would alter the refractory response to the second allergen challenge. 
In the absence of a refractory response, the study design allowed for the assessment of the effect of ibuprofen on 
allergen challenge outcomes, including indices of airway inflammation.
Methods: Thirteen mild atopic asthmatics were enrolled in a randomized, double-blind, placebo controlled, cross-
over study. Ibuprofen (400 mg) or placebo was administered 1 h prior to the first of two allergen challenges, per-
formed 24 h apart. Blood and sputum eosinophils, airway responsiveness to methacholine and levels of fractional 
exhaled nitric oxide were assessed before and 7 h after each allergen challenge. All data were log transformed and 
differences in geometric means were analyzed by paired t-tests.
Results: After placebo, early asthmatic responses for the two challenges were not significantly different (p = 0.82). A 
single 400 mg dose of ibuprofen decreased both the early (p = 0.03; n = 12) and late asthmatic responses (p = 0.03; 
n = 3).
Conclusion: Allergen challenges conducted 24 h apart do not exhibit refractoriness. Single dose ibuprofen inhibits 
early and late asthmatic responses to allergen bronchoprovocation. Ibuprofen should be withheld for at least 24 h 
prior to investigations utilizing allergen bronchoprovocation.
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Background
The allergen bronchoprovocation model is a use-
ful method for studying allergic airway responses and 
assessing novel therapeutics [1, 2]. Bronchoprovo-
cation stimuli have been categorized as direct (e.g. 
methacholine, histamine) or indirect acting (e.g. exer-
cise, mannitol) [3, 4]. By definition, the bronchoconstric-
tion caused by allergic stimuli occurs through an indirect 
mechanism. A phenomenon commonly seen with indi-
rect acting stimuli is refractoriness [5–8]. Refractoriness 
refers to a diminished airway response to a given stimuli 
when a subsequent challenge is performed within a rela-
tively short time frame (e.g. 3 h). Cross refractoriness has 
also been shown when different indirect stimuli are used, 
such as between exercise and sodium metabisulphite 
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[9–11]. We also recently documented a decrease in man-
nitol responsiveness 24  h after allergen challenge [12]. 
Although the measurement of the lessened response was 
made at a significantly longer timepoint than that previ-
ously reported for refractoriness, it is possible that there 
is a cross refractory response between these two indirect 
stimuli at this timepoint. Various mechanisms including 
depletion of mast cell mediators, airway smooth mus-
cle receptor downregulation and protection afforded by 
prostaglandins are possible mechanisms leading to the 
development of refractoriness. These have been recently 
reviewed [13]. Non-steroidal anti-inflammatory drugs 
(NSAIDs) such as ibuprofen inhibit cyclooxygenase 
(COX) enzyme activity (non-selective inhibition of both 
COX-1 and COX-2 enzymes) and subsequently decrease 
protective prostaglandin production. Indomethacin 
has been shown to inhibit the refractory response seen 
with repeated exercise challenges [14] and this sup-
ports the protective prostaglandin theory. If a weakened 
response were to occur after a second allergen chal-
lenge, prostaglandins known to protect the airway from 
bronchoconstriction may be involved. The development 
of a refractory response following repeat allergen chal-
lenge and the role of NSAID treatment on the refrac-
tory response, if it develops, has not been investigated. 
We studied airway responses to allergen challenges per-
formed 24 h apart and assessed the effect of ibuprofen on 
the refractory response, if it developed. In the absence of 
a refractory response, the study design allowed for the 




Participants included males and females between the 
ages of 18–70  years with mild asthma and a positive 
methacholine challenge (methacholine PC20 ≤16  mg/
mL), baseline percent predicted FEV1 ≥70  % and a 
positive skin prick test to at least one allergen that could 
be aerosolized for inhalation challenge. Participants 
were excluded if they were using controller medications, 
reported a sensitivity to aspirin or other NSAID or had 
a respiratory infection or significant asthma exacerbation 
within the 4 weeks prior to screening. As needed salbu-
tamol was allowed but withheld for at least 6 h prior to 
the start of each visit. Female participants could not be 
pregnant or lactating.
Study design
We performed a randomized, double-blind, placebo 
controlled crossover investigation. After a screening/
randomization visit, participants underwent two identi-
cal, consecutive day triads of testing separated by at least 
13  days. Peripheral blood and sputum were collected 
on Day 1 of each triad. Fractional exhaled nitric oxide 
(FeNO) levels and methacholine responsiveness were 
also assessed on Day 1 of each triad. Participants under-
went allergen inhalation challenges on triad Days 2 and 
3. Blood, sputum, FeNO and airway sensitivity to metha-
choline were again assessed at 7 h post allergen challenge 
on triad Days 2 and 3. Levels of FeNO were also meas-
ured pre allergen challenge on triad Day 3. Participants 
self-administered either 400  mg of ibuprofen or match-
ing blinded placebo 1 h prior to each triad Day 2 allergen 
challenge. A study schematic is depicted in Table 1.
Dosing and blinding
Ibuprofen (200 mg Advil®) gel capsules were purchased 
from a local pharmacy. Identical appearing placebo (lac-
tose filled #00 capsules) and 200  mg ibuprofen (encap-
sulated in #00 capsules) were prepared by a local health 
region pharmacy. Individual treatments consisted of 
two capsules of placebo and two capsules of ibuprofen. 
The order in which a given participant took the treat-
ments was random. A health region research pharma-
cist created the randomisation code and packaged the 
Table 1 Study schematic
MCh methacholine challenge; FeNO fractional exhaled nitric oxide; SI sputum induction; AC allergen challenge; Dose placebo or 400 mg ibuprofen 1 h pre AC1
Visit 1 Triad 1 Washout Triad 2
Screening n = 16 Randomization n = 13 Visit 2 Visit 3 Visit 4 Visit 5 Visit 6 Visit 7
Day 1 Day 2 Day 3 Day 1 Day 2 Day 3




n = 5 to placebo
first




































Page 3 of 8Nomani et al. Allergy Asthma Clin Immunol  (2016) 12:24 
treatments. The randomisation code was broken after all 
participants completed testing.
Skin prick testing
Skin prick testing was performed to determine par-
ticipant atopy status and identify a suitable allergen for 
use in the allergen inhalation challenge. Drops of posi-
tive control, negative control and 22 common allergens 
including seasonal pollens, animals, food, and fungus 
were placed on the volar surface of the forearm and 
introduced to the body by a “tenting” of the skin with 
a lancet. A wheal size of 3  mm or greater, 10  min after 
tenting was considered positive. The largest wheal, type 
of allergen (i.e. not food or fungus) and clinical history 
on exposure to the allergen (i.e. development/severity of 
symptoms) determined which allergen would be chosen 
for the inhalation challenge.
Fractional exhaled nitric oxide (FeNO)
Fractional exhaled nitric oxide levels were measured 
using the NIOX Mino instrument (Aerocrine AB, Swe-
den). Participants inhaled fully on the filter mouthpiece 
and then exhaled at a constant flow rate (50  mL/s) for 
10  s. Two reproducible measurements (parts per bil-
lion, ppb ± 10 %) were recorded and the average used for 
analyses [15]. Triad Day 1 and Day 3 baseline measure-
ments were taken prior to any other procedures being 
performed. Triad Day 2 post allergen challenge levels 
were measured immediately before the 7  h spirometry 
maneuver.
Blood
Venous blood was collected the day before and at 7  h 
after each allergen challenge during both triads. Com-
plete and differential blood counts were performed by a 
local health region lab.
Sputum induction and processing
Participants were pretreated with 200  mcg salbutamol 
before inhaling increasing concentrations (3, 4, and 5 %) 
of hypertonic saline. Each concentration was inhaled for 
7  min using the DeVilbiss Ultra-NEB 99. Participants 
were required to blow their nose and rinse their mouth 
with water before trying to produce a sample.
Samples were refrigerated immediately after collection 
and then processed within 2 h of collection. Mucus plugs 
were selected from the entire sample, treated with dithi-
othreitol, washed with phosphate buffered saline (PBS) 
and filtered, as previously described [16]. A 0.01 mL ali-
quot of this cell suspension was used to determine the 
total cell count and viability of the sample (trypan blue 
exclusion method). The cell suspension was then centri-
fuged for 10 min at 750g. The supernatant was drawn off 
and immediately frozen for future use. The cell pellet was 
re-suspended with PBS to generate 1 × 106 cells/ml and 
0.04 mL aliquots of the cell suspension were used to pre-
pare duplicate cytospins. Slides were stained with Kwik 
Diff (Thermo Scientific). Duplicate differential cell counts 
were performed in a blinded fashion under 400× mag-
nification (40× lens and 10× eyepiece). A minimum of 
400 non-squamous cells were counted and the number of 
eosinophils was expressed as a percentage of total cells. 
The average of the duplicate percentages was used for 
analyzing changes in sputum eosinophil content.
Methacholine challenge
Methacholine challenges were conducted according to 
the standardized 2 min tidal breathing methodology [17]. 
In brief, three reproducible full flow-volume spirograms 
were captured to assess baseline lung function and air-
way stability. Diluent or doubling concentrations of 
methacholine solutions were generated from a jet nebu-
lizer (Bennett Twin) at a rate of 0.13 ml/min. With nose 
clips in place, a mask placed loosely over the nose and 
mouth directed the aerosol toward the mouth for inha-
lation. After 2 min of inhalation, spirometric maneuvers 
were performed at 30 and 90 s post inhalation to capture 
FEV1 data only. The lesser of these values was used for 
calculating the decrease in FEV1 relative to the lowest 
FEV1 following diluent inhalation. The time interval from 
the start of one inhalation to the start of the next inhala-
tion was 5 min. The test was stopped when a fall in FEV1 
was ≥17  %. Methacholine PC20 values were calculated 
either by interpolation [18] or extrapolation [19] from the 
log concentration versus response curve.
Allergen challenge
Allergen inhalation challenges were performed using a 
2 min tidal breathing methodology. Prior to inhaling aller-
gen, three reproducible baseline full flow volume spiro-
metric measurements were obtained. Aerosolized allergen 
was then administered by way of the Wright Nebulizer 
(Roxon Medi-Tech, Montreal, Quebec, Canada) fitted 
with a two way Hans-Rudolph valve and calibrated to 
deliver an output of 0.13 ml/min. Two filters were placed 
on the expiratory port of the two way valve to protect 
ambient air from contamination with exhaled allergen. 
By way of mouthpiece and with nose clips in place, par-
ticipants inhaled doubling concentrations of aerosolized 
allergen during 2 min of tidal breathing. The starting con-
centration was 3–4 dilutions below a participants’ pre-
dicted allergen PC20 and this was constant throughout 
the study. The predicted allergen PC20 was determined 
using the skin test endpoint and screening methacholine 
PC20 [20]. Ten minutes after inhalation, two FEV1 meas-
urements were obtained 1 min apart. The highest of the 
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two post allergen FEV1 values was compared to the high-
est baseline FEV1 to calculate the percent fall in FEV1. The 
criterion for stopping allergen inhalations during the first 
allergen challenge was a fall in FEV1 of at least 20 %. All 
subsequent allergen challenges were stopped when the 
same dose of allergen had been delivered or when safety 
considerations made stopping necessary. Lung function 
was then monitored at 20, 30, 45, 60, 90, and 120 min post 
inhalation, and then hourly up to 7 h post challenge. The 
early asthmatic response (EAR PC20) and the late asth-
matic response (LAR PC15) are presented as the concen-
tration of allergen required to cause a 20  % fall in FEV1 
from 0 to 3 h post allergen inhalation and a 15 % fall in 
FEV1 from 3 to 7 h post allergen inhalation, respectively.
Statistical analysis
Data were analysed using Statistix 10.0 software (Tal-
lahassee, Florida). EAR PC20, LAR PC15, methacholine 
PC20, blood eosinophils, sputum eosinophils and FeNO 
data were log transformed prior to paired t test compari-
son. Data are reported as geometric mean with 95 % con-
fidence intervals unless stated otherwise.
Results
Participants
Sixteen individuals volunteered to participate in the study 
and underwent screening procedures. Thirteen individuals 
met the inclusion/exclusion criteria and were enrolled in 
the study. Eleven participants completed the study (Table 2). 
One participant (#011) was withdrawn the morning of the 
fourth allergen challenge (triad 2  day 2) due to decreased 
lung function. Data collected from the previous visits was 
included in the analysis. Another participant (#013) was 
withdrawn at the start of the third allergen challenge (triad 
2 day 1) due to worsened asthma control. Data previously 
collected on this participant was not included in the analy-
sis as the participant was randomised to receive ibuprofen 
treatment first. Late asthmatic responses were observed in 
three participants. There were no serious adverse events.
Allergen challenge refractoriness
After placebo, the EAR PC20 of the second allergen chal-
lenge was not significantly different from the first aller-
gen challenge [250 units/ml (79–790) versus 225 units/
ml (82–617); p = 0.82]. The response to a second allergen 
challenge conducted 24  h after an initial allergen chal-
lenge is not refractory.
Early asthmatic response
The EAR PC20 increased from 225 units/ml (82–617) 
after placebo to 356 units/ml (125–1017) after 400  mg 
ibuprofen indicating that the response to allergen was 
significantly inhibited by a single dose of ibuprofen 
(p =  0.03). The EAR PC20 of the second post ibuprofen 
allergen challenge was 213 units/ml (73–619) and not 
significantly different from the first or second allergen 
challenge EAR PC20 after placebo (Fig. 1). This suggests 
the inhibitory effect of ibuprofen was gone at 24 h.
Late asthmatic response
The LAR PC15 after placebo was 57 units/ml (1.3–2630), 
and the LAR PC15 after ibuprofen was 208 units/ml (5.2–
8318); p =  0.03; n =  3. Two participants had decreases 
in FEV1 > 7.5 % during the 3–7 h post allergen challenge. 
We extrapolated LAR PC15 values from these data and 
this allowed for an increase in the LAR sample size, from 
Table 2 Participant demographics
Standardized timothy grass 100,000 BAU/ml; Standardized HDM- DP 30,000 AU/mL; standardized cat pelt 10,000 BAU/ml; EAR: isolated early asthmatic response; DAR: 
dual asthmatic response (has both an early and a late asthmatic response)
Participant Age (years) Gender Height (cm) FEV1 (L) FEV1
(% predicted)






001 45 F 163 2.53 87 6.0 Timothy grass EAR
002 27 F 159 2.78 90 3.2 HDM-DP EAR
003 49 F 178 2.54 74 5.9 Cat DAR
004 30 M 196 5.39 100 0.97 Cat EAR
005 38 M 178 3.56 83 0.35 Cat EAR
006 22 F 168 3.15 90 14.2 Cat EAR
007 29 F 163 2.86 89 1.4 Cat EAR
008 22 M 185 4.60 92 7.3 Cat EAR
009 20 F 170 3.17 88 2.8 Cat DAR
010 21 M 183 4.30 87 8.5 HDM-DP EAR
011 24 M 180 3.93 83 0.48 Cat DAR
012 68 M 168 2.17 77 0.53 Timothy grass EAR
013 31 F 163 2.25 71 0.13 Cat EAR
Page 5 of 8Nomani et al. Allergy Asthma Clin Immunol  (2016) 12:24 
three to five. Significant inhibition of the LAR was still 
observed with five late responders (placebo treatment 
211 units/ml (12–3724) and ibuprofen treatment 599 
units/ml (57–6283); p = 0.01) (Fig. 2).
Markers of inflammation (blood and sputum eosinophils, 
FeNO and airway responsiveness to methacholine—
Table 3)
Peripheral blood eosinophils numerically increased after 
both allergen challenges following placebo treatment. 
The increase was significant compared to baseline levels 
following the second allergen challenge only (p = 0.001). 
Peripheral blood eosinophils also numerically increased 
after both allergen challenges following ibuprofen treat-
ment. The increases were significant versus baseline as 
well as between the first and second allergen challenges 
(p = 0.003, p = 0.0005 and p = 0.005 respectively).
Following placebo treatment, sputum eosinophils 
increased after the first allergen challenge and further 
increased after the second allergen challenge but neither 
increase reached statistical significance versus baseline. 
After ibuprofen treatment, sputum eosinophils had a sim-
ilar pattern of increases following the allergen challenges 
which reached statistical significance versus baseline as 
well as between the first and second allergen challenges 
(p = 0.05, p = 0.007 and p = 0.02 respectively).
Levels of FeNO were significantly increased versus pre 
allergen challenge values for both the placebo (p = 0.005) 
and the ibuprofen (p = 0.005) treatment arms at 7 h after 
the second allergen challenges.
Allergen exposure did not alter airway responsiveness 
to methacholine following placebo treatment. After ibu-
profen, however, airway responsiveness to methacholine 
was significantly increased after the first allergen chal-
lenge only. The pre challenge methacholine PC20 was 
2.4 mg/ml versus the methacholine PC20 of 1.6 mg/ml at 
7 h after the first allergen challenge (p = 0.04).
Discussion
The primary objective of our current study was to deter-
mine whether airway responses to a second allergen chal-
lenge performed 24  h after the first allergen challenge 
Fig. 1 Early asthmatic responses to the four allergen challenges. 
The data on the left (Placebo AC1 and AC2) depicts the absence of 
refractoriness. The data on the right shows the inhibitory effect of 
ibuprofen (ibuprofen AC1 versus placebo AC1) and the duration of 
the inhibition (ibuprofen AC1 versus ibuprofen AC2). Data are pre-
sented as the geometric mean allergen PC20. Error bars represent the 
standard error of the mean SEM. The time interval between AC1 and 
AC2 for each treatment is 24 h
Fig. 2 Inhibitory effect of ibuprofen on the late asthmatic response in 3 (a) and 5 (b) late responders. Data are presented as the geometric mean 
allergen PC15. Error bars represent the standard error of the mean SEM
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exhibit a refractory state. We observed that the early 
asthmatic response to a second allergen challenge was 
unchanged compared to that of the first challenge indi-
cating a refractory state does not develop when allergen 
challenges are performed 24  h apart. Refractoriness is 
common with non-allergic indirect acting stimuli includ-
ing exercise [6], adenosine monophosphate [7] and 
mannitol [8]. Cross refractoriness has also been shown 
between exercise and metabisulphate [9], exercise and 
AMP [11] and allergen and mannitol [5, 12]. Both allergic 
and non-allergic indirect acting stimuli trigger the release 
of bronchoconstricting mediators from mast cells. The 
similar mechanisms of bronchoconstriction and the pres-
ence of cross refractoriness suggested allergic indirect 
acting stimuli might also exhibit a refractory response to 
repeat challenge. Although both stimuli trigger mast cell 
degranulation, the IgE mediated allergic pathway, a type 
I hypersensitivity reaction, is much more complex than 
that of non-allergic stimuli and this may explain the lack 
of refractoriness with repeat allergen challenge. Another 
possible explanation is that the timeframe between chal-
lenges (i.e. 24  h) needs to be shorter such that the sec-
ond challenge is performed soon after recovery from the 
initial challenge. The importance of duration between 
challenges likely relates to depletion of mast cell media-
tors as the mechanism leading to refractoriness. A longer 
duration between challenges would favor the absence 
of a refractory state but recent data from Larsson et  al. 
suggests mast cell mediator depletion is not a causal fac-
tor in the development of refractoriness [21]. Addition-
ally, cross refractoriness has been shown to be present 
at both 3 and 24 h after the initial allergen challenge [5, 
12]. Investigations of mannitol challenges performed 
24 h apart, of airway responses to allergen challenge after 
recovery from mannitol challenge and of repeat allergen 
challenges within a shorter timeframe may provide addi-
tional insight into the mechanism(s) of refractoriness and 
cross refractoriness of indirect acting stimuli.
Given that we did not observe a refractory response 
with repeat allergen challenge, the effect of ibuprofen 
on the development of refractoriness was a moot point. 
However, in addition to the role of protective prostaglan-
dins in the mechanism of refractoriness as evidenced 
by loss of refractoriness following indomethacin pre-
treatment [14], it is also possible that blocking the pro-
duction of protective prostaglandins would lead to the 
development of a late asthmatic response in isolated early 
responders. It may be of interest to note therefore, as an 
ad hoc assessment that late responses, or a signal for the 
development of a late response, did not occur following 
ibuprofen treatment in those who showed isolated early 
responses.
Our study design allowed for the assessment of ibu-
profen on airway responses to allergen challenge if 
refractoriness did not develop. We have shown signifi-
cant inhibition of the EAR after a single 400 mg dose of 
ibuprofen administered 1  h prior to allergen exposure. 
The protection was gone at 24  h, consistent with the 
pharmacokinetics of ibuprofen and the study design. 
We reviewed five investigations in which the effect of 
NSAID’s on allergen challenge had been reported [22–
26]. With the exception of the Joubert et  al. [23] study, 
which treated participants with 100  mg/day of indo-
methacin for 3 days, treatment with NSAID’s were inef-
fective in decreasing the EAR. Conversely, with respect 
to the LAR, four of the five studies we reviewed docu-
mented significant inhibition of the LAR [22, 23, 25, 
26] and our data are consistent with the literature. We 
showed significant inhibition of the LAR in three “bona 
fide” late responders (i.e. decrease in FEV1 ≥15 % in the 
3–7 h post allergen challenge). By including participants 
that had a fall in FEV1 of ≥7 % in the 3–7 h after aller-
gen challenge, our LAR sample size increased to 5 and 
the inhibition of the LAR showed even greater statisti-
cal significance (p =  0.01 versus p =  0.03). The LAR is 
commonly reported as the maximal fall in FEV1 or area 
under the curve (AUC). Meaningful interpretation of the 
LAR using these endpoints requires that the same dose 
of allergen be administered across all allergen challenges. 
Due to safety considerations, we were unable to adminis-
ter the same dose of allergen during all four allergen chal-
lenges in 58 % of our participants (i.e. FEV1 fell ≥20 % at 
Table 3 Changes in markers of inflammation
Data are presented as the geometric mean (95 % confidence intervals)
AC allergen challenge; EOS eosinophils; FeNO fractional exhaled nitric oxide and MCh PC20 concentration of methacholine causing a 20 % fall in FEV1
Treatment Timepoint Blood EOS (x109/L) Sputum EOS (%) FeNO (ppb) MCh PC20 (mg/mL)
Placebo pre AC (baseline) 0.17 (0.11–0.26) 5.1 (2.7–9.6) 29.5 (19.7–44.2) 1.9 (0.95–3.8)
7 h post AC1 0.20 (0.14–0.28) 8.2 (3.1–21.9) 33.2 (22.3–49.4) 1.9 (0.95–4.1)
7 h post AC2 0.23 (0.16–0.34) 12.1 (4.2–35.0) 39.0 (25.4–59.9) 1.7 (0.96–3.1)
Ibuprofen pre AC= (baseline) 0.14 (0.08–0.25) 4.0 (2.1–7.8) 29.7 (19.6–44.8) 2.4 (0.99–5.8)
7 h post AC1 0.21 (0.14–0.31) 8.6 (3.4–21.8) 30.5 (17.9–52.1) 1.6 (0.70–3.5)
7 h post AC2 0.26 (0.18–0.39) 14.1 (7.0–28.5) 40.8 (24.4–68.3) 1.5 (0.73–3.2)
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a weaker concentration of allergen than that given dur-
ing the first allergen challenge). We controlled for differ-
ences in the dose of allergen administered by assessing 
and reporting the airway responses to allergen as the 
EAR PC20 and LAR PC15. This methodological difference 
may explain the discrepancy in the effect of NSAID’s on 
the EAR between our current data and data previously 
reported.
Studies that employ repeat allergen exposure (e.g. low 
dose allergen challenge methodology) have shown wors-
ened asthma outcomes, including increases in symptoms, 
rescue therapy, inflammatory markers and worsened air-
way responses (i.e. FEV1, EAR, LAR) [27–29]. The simi-
lar EAR PC20 data following the placebo treatment in 
our current study do not suggest a priming effect of the 
first allergen challenge on airflow responses to a second 
allergen challenge. The study populations in which wors-
ened responses have occurred following repeat allergen 
challenges focus on late responders. Our mixed study 
population of both early and late responders, predomi-
nantly early, may explain the absence of a priming effect 
and review of the raw data in the three bona fide late 
responders strongly supports a priming effect.
Well-documented consequences of allergen exposure 
in dual responders include increased airway respon-
siveness to methacholine, increased levels of fractional 
exhaled nitric oxide and increased peripheral blood and 
sputum eosinophils. The presence of a late asthmatic 
response was not an entrance criteria in the current study 
and, as previously mentioned, dual responders accounted 
for a small portion of our study population. Nonethe-
less, in our study population as a whole, following both 
placebo and ibuprofen treatment, levels of sputum and 
peripheral blood eosinophils as well as FeNO increased 
after the first allergen challenge and further increased 
after the second allergen challenge. The magnitude of the 
increases tended toward statistical significance following 
ibuprofen. In addition, airway responsiveness to metha-
choline did not increase significantly after placebo but 
did increase significantly after ibuprofen. The increase 
in methacholine responsiveness following ibuprofen was 
less than one concentration, which is probably not clini-
cally relevant. The sequelae data must be interpreted 
with caution for two reasons. First, the amount of aller-
gen administered across all allergen challenges was not 
consistent. It is worth noting however that the amount 
of allergen delivered was always less and this would not 
intuitively translate to the observed increases in airway 
responses. Second, our study population includes indi-
viduals with either isolated early or dual responses and 
much of what we appreciate about airway inflammation 
following allergen challenge is based on findings in dual 
responders.
Ibuprofen and other NSAID’s non-selectively inhibit 
cyclooxygenase enzyme activity and decrease the produc-
tion of prostaglandins (PG’s) and thromboxanes (TXA’s). 
These eicosanoids, along with other arachidonic acid 
metabolites generated by lipoxygenase enzymes have 
a wide range of physiological effects, many of which are 
relevant to the airway responses induced by allergen 
exposure in atopic asthmatics. In the absence of mecha-
nistic data it is difficult to postulate how a single dose of 
ibuprofen led to a decrease in early and late asthmatic 
responses. We have previously reported inhibition of 
early and late asthmatic responses following single dose 
montelukast, which targets the lipoxygenase pathway 
of eicosanoid production [30, 31]. If we consider down-
stream effects of cyclooxygenase inhibition, we anticipate 
a decrease in the production of the different prostaglan-
din isoforms and a subsequent decrease in their related 
effects. For example, PGD2 is known to cause bronchoc-
onstriction and blocking the production of PGD2 should 
therefore produce an inhibitory effect on the early asth-
matic response. Conversely, PGE2 is bronchoprotective 
[32, 33] and decreasing levels of PGE2 might be expected 
to worsen airway responses to allergen challenge. Another 
possible outcome of cyclooxygenase inhibition is a shift in 
eicosanoid production away from prostaglandin synthesis 
toward lipoxygenase generated eicosanoid synthesis. This 
has been proposed as a mechanism by which worsened 
asthma responses are observed following the use of the 
COX-1 inhibitor aspirin [34]. If leukotriene production 
increases following ibuprofen treatment, a greater or at 
least similar response to allergen challenge, as has been 
observed with etorocoxib [35] might be expected.
Conclusions
The refractory response seen with repeat challenge to 
non-allergic indirect acting stimuli does not occur with 
IgE mediated stimuli in mild atopic asthmatics. In these 
same individuals, a single 400  mg dose of ibuprofen 
decreases both early and late asthmatic responses. Ibu-
profen, and possibly other NSAID’s, should be withheld 
for at least 24  h prior to investigations using allergen 
challenge methodology.
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